secwatch.observer — SEC 8-K summary
======================================

Issuer:     Cytek Biosciences, Inc. (CTKB)
CIK:        0001831915
Form:       8-K
Filed at:   2023-11-07T23:59:59+00:00
Accession:  0001193125-23-272504
Event type: earnings
Sentiment:  negative
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cytek Q3 revenue $48M (+19%), organic growth 2%; net loss $6.5M; FY guidance $188-192M
--------------------------------------------------------------------------------

- Total revenue $48.0M (+19% YoY); organic revenue $41.2M (+2%); acquired Luminex contributed $6.8M.
- Gross profit margin 57% vs 66% prior year; adjusted gross margin 59% vs 68%.
- Operating loss $6.4M vs income $1.4M; net loss $6.5M vs net income $1.6M; adjusted EBITDA $3.7M vs $7.3M.
- FY 2023 revenue guidance $188-192M (15-17% growth); organic expected flat vs 2022.
- Repurchased 1,155,229 shares at $8.4M; cash $288M, down from $344M at Dec 2022.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1831915/000119312523272504/0001193125-23-272504-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1831915/000119312523272504/d556029d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-272504

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer